Autolus Therapeutics (NASDAQ:AUTL) Upgraded to Buy at Redburn Atlantic

Redburn Atlantic upgraded shares of Autolus Therapeutics (NASDAQ:AUTL) from a neutral rating to a buy rating in a report released on Friday, Marketbeat Ratings reports. They currently have $13.00 price objective on the stock.

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $9.00 price target on shares of Autolus Therapeutics in a research report on Monday, November 11th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Autolus Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $9.45.

Autolus Therapeutics Price Performance

AUTL stock traded up $0.07 during midday trading on Friday, reaching $3.08. 2,714,678 shares of the stock were exchanged, compared to its average volume of 1,442,195. The stock has a market capitalization of $819.56 million, a PE ratio of -2.55 and a beta of 2.04. Autolus Therapeutics has a 52 week low of $2.94 and a 52 week high of $7.45. The company has a fifty day moving average price of $3.91 and a 200 day moving average price of $3.98.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period last year, the company posted ($0.26) earnings per share. As a group, analysts anticipate that Autolus Therapeutics will post -0.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC boosted its position in shares of Autolus Therapeutics by 253.5% during the 2nd quarter. Renaissance Technologies LLC now owns 1,145,056 shares of the company’s stock valued at $3,985,000 after purchasing an additional 821,156 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in Autolus Therapeutics by 82.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock worth $35,020,000 after buying an additional 2,487,778 shares during the period. Millennium Management LLC raised its stake in Autolus Therapeutics by 113.7% during the 2nd quarter. Millennium Management LLC now owns 813,031 shares of the company’s stock worth $2,829,000 after buying an additional 432,503 shares during the period. BNP Paribas Financial Markets raised its stake in Autolus Therapeutics by 2,603.8% during the 1st quarter. BNP Paribas Financial Markets now owns 115,399 shares of the company’s stock worth $736,000 after buying an additional 111,131 shares during the period. Finally, Affinity Asset Advisors LLC raised its stake in Autolus Therapeutics by 27.4% during the 2nd quarter. Affinity Asset Advisors LLC now owns 4,300,000 shares of the company’s stock worth $14,964,000 after buying an additional 925,000 shares during the period. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.